Novo Nordisk and Hims & Hers have entered into a partnership that will allow the telehealth platform to sell the company’s obesity drugs Wegovy and Ozempic. The agreement, announced on March 9, 2026, resolves a legal dispute that began in February when Novo Nordisk sued Hims & Hers for marketing unapproved versions of the drugs. Under the new arrangement, Hims & Hers will offer Wegovy and Ozempic at the same self‑pay prices as other telehealth partners, giving the company a dedicated channel for its FDA‑approved injectables while maintaining exclusivity only on its own platform.
The partnership is part of Novo Nordisk’s broader strategy to strengthen its U.S. market penetration and to counter competition from Eli Lilly’s tirzepatide and the growing gray market of compounded semaglutide. By securing a direct‑to‑consumer distribution partner, Novo aims to reinforce pricing power and expand volume opportunities for its GLP‑1 portfolio, while Hims & Hers gains a credible, FDA‑approved product line that can attract new subscribers and reduce regulatory risk.
Novo Nordisk’s recent financial performance underscores the strategic importance of the deal. In Q4 2025 the company reported earnings per share of $1.01 versus analyst expectations of $0.90, and revenue of $12.43 billion against estimates of $11.97 billion. However, the company has issued 2026 guidance that projects adjusted sales growth of –5% to –13% at constant exchange rates, a decline that reflects pricing pressure, competition, and patent expirations in some markets. Management has acknowledged the “unprecedented pricing pressure” while emphasizing a focus on volume growth in obesity and diabetes.
The partnership delivers immediate benefits to both parties. For Hims & Hers, it eliminates a major legal overhang and provides access to a high‑demand drug line, positioning the company to capture a larger share of the U.S. GLP‑1 market. For Novo Nordisk, the deal mitigates litigation risk and creates a new sales channel that can help offset the headwinds reflected in its 2026 guidance. The arrangement signals Novo’s commitment to expanding direct‑to‑consumer access while navigating a competitive landscape that includes Eli Lilly’s tirzepatide and a persistent gray‑market threat.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.